Korean J Hematol.  2005 Jun;40(2):124-128. 10.5045/kjh.2005.40.2.124.

Reversal of Marrow Fibrosis Following Imatinib Mesylate Therapy in a Patient with Chronic Myelogenous Leukemia Who Was Refractory to Interferon-alpha

• Kim YS
• Kim TH
• Kim WC
• Jeon YJ
• Kil UH
• Lee HK
• Kim YS
• Rho SY
• Cho SG

• KMID: 2252349
• DOI: http://doi.org/10.5045/kjh.2005.40.2.124

Abstract

No abstract available.

Keyword

Imatinib mesylate; Chronic myelogenous leukemia; Marrow fibrosis

MeSH Terms

Bone Marrow*
Fibrosis*
Humans
Interferon-alpha*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
Mesylates*
Imatinib Mesylate
Interferon-alpha
Mesylates

Figure

• 

  Fig. 1. (A) Bone marrow biopsy section at the time of diagnosis shows marked fibrosis (H-E stain, × 100). (B) Bone marrow biopsy at the time of diagnosis shows extensive reticulin fibrosis (reticulin stain, × 100). (C) After 12 months of imatinib therapy, bone marrow aspiration shows the normocellular marrow (H&E stain, × 40). (D) After 12 months of imatinib therapy, no reticulin fibrosis is found on biopsy section (reticulin stain, × 40).

Reference

1). Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999; 341:164–72.

2). O'Brien SG, Guilhot F, Larson RA, et al. IRIS investigators: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348:994–1004.

3). Bueso-Ramos CE, Cortes J, Talpaz M, et al. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer. 2004; 101:332–6.

4). Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood. 2002; 99:381–3.

5). Wilhelm M, Bueso-Ramos C, O'Brien S, et al. Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia. 1998; 12:65–70.

6). Buesche G, Hehlmann R, Hecker H, et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective longterm results from a randomized-controlled trial. Leukemia. 2003; 17:2444–53.

7). Buesche G, Freund M, Hehlmann R, et al. German CML study group: Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the longterm results from two prospective controlled trials on chronic myeloid leukemia. Leukemia. 2004; 18:1460–7.

8). Kvasnicka HM, Thiele J, Schmitt-Graeff A, et al. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph (1+) chronic myelogenous leukemia: a multicenter trial. J Clin Oncol. 2001; 19:2994–3009.

9). Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study. Br J Haematol. 2000; 108:64–71.

10). Laughlin M, Islam A, Barcos M, et al. Effect of alpha-interferon therapy on bone marrow fibrosis in hairy cell leukemia Blood. 1988; 72:936–9.

11). Kaban K, Kantarjian H, Talpaz M, et al. Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy. Cancer. 2000; 88:570–6.

12). Yang M, Khachigian LM, Hicks C, Chesterman CN, Chong BH. Identification of PDGF receptors on human megakaryocytes and megakaryocytic cell lines. Thromb Haemost. 1997; 78:892–6.

13). Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000; 295:139–45.